SAN RAFAEL, Calif., June 26, 2019 /PRNewswire/ —¬†BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that Professor John Pasi, M.B., Ch.B., Ph.D., from Barts and the London School of Medicine and Dentistry and principal investigator for the valoctocogene roxaparvovec Phase 1/2 study (BMN 270-201) and the Phase 3 study (BMN 270-301) will present data in a late breaking abstract session at the International Society on Thrombosis and Haemostasis (ISTH) 2019 Congress being held July 6-10, 2019 in Melbourne, Australia.

https://www.ptcommunity.com/wire/biomarin-announces-acceptance-late-breaking-abstract-international-society-thrombosis-and

Share this story, choose your platform!